Skip to main content

Advertisement

Table 3 Baseline and follow-up values and changes in haemoglobin concentration within 10 days post-treatment in participants who received AL + SLD PQ (n = 87)

From: Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study

Characteristic Mean (SD) (range)
Baseline haemoglobin (g/dL) 11.6 (2.3) [8–20.1]
Follow-up haemoglobin (g/dL) 11.0 (1.8) [7.2–15.8]
Absolute change in haemoglobin (g/dL) −0.6 (1.6) [−5.9–3]
Percent change in haemoglobin (g/dL) −3.7 (12.7) [−31.4–30.9]
  1. Primaquine was given on day 0 of treatment, together with dose 1 of artemether-lumefantrine. Mean absolute change defined as the haemoglobin mean on the day of follow-up minus the haemoglobin mean at day 0. Mean relative percentage change between day 0 (t1) and follow-up (t2) defined as [(hb(t2)−hb(t1))/hb(t1)] × 100
  2. AL artemether-lumefantrine, Hb haemoglobin, SLD PQ single low-dose primaquine, SD standard deviation